Glenmark receives ANDA approval for Calcipotriene Cream
11 June 2015 | News | By BioSpectrum Bureau
Glenmark receives ANDA approval for Calcipotriene Cream
The drug is the therapeutic equivalent of Dovonex Cream
Glenmark Pharmaceuticals has been granted final approval by the United States Food and Drug Administration (US FDA) for Calcipotriene Cream, 0.005 percent. The drug is the therapeutic equivalent of Dovonex Cream, 0.005 percent of Leo Pharma A/S.
The company plans to commence shipping of Calcipotriene Cream, 0.005 percent immediately.
According to IMS Health sales data for the 12 month period ending April 2015, the Dovonex market achieved annual sales of approximately $91.9 million.
